StockData
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. (NERV) stock

NERVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$2.16−0.04 (-1.82%)

Close on Nov 17, 2026Market cap $103.14MP/E –Yield –

Minerva Neurosciences total assets

Total assets on the balance sheet at the end of each period.

Minerva Neurosciences's total assets was $95.09M at Jun 30, 2026. For fiscal 2025 it was $97.97M, up 163.8% from the year before. Over ten years it grew 1.7% a year on average. The highest annual figure on record is $183.70M in fiscal 2017.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$97.97M+163.8%
FY2024Dec 31, 2024$37.14M-34.7%
FY2023Dec 31, 2023$56.90M+3.3%
FY2022Dec 31, 2022$55.09M-28.6%
FY2021Dec 31, 2021$77.12M+33.8%
FY2020Dec 31, 2020$57.63M-25.6%
FY2019Dec 31, 2019$77.50M-44.3%
FY2018Dec 31, 2018$139.14M-24.3%
FY2017Dec 31, 2017$183.70M+38.2%
FY2016Dec 31, 2016$132.94M+61.0%
FY2015Dec 31, 2015$82.58M+20.6%
FY2014Dec 31, 2014$68.45M+134.6%
FY2013Dec 31, 2013$29.17M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$95.09M+212.6%
Q1 FY2026Mar 31, 2026$94.03M+186.7%
Q4 FY2025Dec 31, 2025$97.97M+163.8%
Q3 FY2025Sep 30, 2025$28.09M-34.4%
Q2 FY2025Jun 30, 2025$30.42M-34.3%
Q1 FY2025Mar 31, 2025$32.80M-35.1%
Q4 FY2024Dec 31, 2024$37.14M-34.7%
Q3 FY2024Sep 30, 2024$42.81M-32.2%
Q2 FY2024Jun 30, 2024$46.29M-31.1%
Q1 FY2024Mar 31, 2024$50.51M-2.1%
Q4 FY2023Dec 31, 2023$56.90M+3.3%
Q3 FY2023Sep 30, 2023$63.13M+5.6%
Q2 FY2023Jun 30, 2023$67.14M+3.4%
Q1 FY2023Mar 31, 2023$51.59M-26.9%
Q4 FY2022Dec 31, 2022$55.09M-28.6%
Q3 FY2022Sep 30, 2022$59.76M-38.7%
Q2 FY2022Jun 30, 2022$64.96M-38.3%
Q1 FY2022Mar 31, 2022$70.62M-36.9%
Q4 FY2021Dec 31, 2021$77.12M+33.8%
Q3 FY2021Sep 30, 2021$97.56M+49.6%
Q2 FY2021Jun 30, 2021$105.32M+59.2%
Q1 FY2021Mar 31, 2021$111.83M+62.6%
Q4 FY2020Dec 31, 2020$57.63M-25.6%
Q3 FY2020Sep 30, 2020$65.22M-41.1%
Q2 FY2020Jun 30, 2020$66.17M-45.0%
Q1 FY2020Mar 31, 2020$68.79M-47.0%
Q4 FY2019Dec 31, 2019$77.50M-44.3%
Q3 FY2019Sep 30, 2019$110.81M-26.4%
Q2 FY2019Jun 30, 2019$120.29M-25.3%
Q1 FY2019Mar 31, 2019$129.80M-25.6%
Q4 FY2018Dec 31, 2018$139.14M-24.3%
Q3 FY2018Sep 30, 2018$150.53M-22.2%
Q2 FY2018Jun 30, 2018$160.94M+26.3%
Q1 FY2018Mar 31, 2018$174.47M+28.9%
Q4 FY2017Dec 31, 2017$183.70M+38.2%
Q3 FY2017Sep 30, 2017$193.51M+36.5%
Q2 FY2017Jun 30, 2017$127.38M–
Q1 FY2017Mar 31, 2017$135.31M–
Q4 FY2016Dec 31, 2016$132.94M–
Q3 FY2016Sep 30, 2016$141.72M–

More Minerva Neurosciences figures

See a number that looks wrong?